Abstract: With the clinical applications of new immunotherapies, traditional TNM staging has been unable to meet the clinical needsof curative effect predictions. It is known that the immunological features of the tumor immune microenvironment play importantroles in tumor prognosis evaluations. Recently, the immunoscore system, which is based on local immune cell distribution and density, has gradually become an important indicator for prognosis evaluations and has been verified in several tumor researches. Recently, with the application of new mass flow detection and single cell sequencing technologies, the number of immune landscape studieshave also been increasing, and new tumor-specific immune cell subsets have been identified. These subtypes not only provide individualized immunotherapy guidelines for patients, but also provide potential new targets for the further development of new immunotherapy strategies. This review will introduce recent research progress in this field.